Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by NewAmsterdam Pharma Company B.V.

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present at Jefferies Healthcare Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present at Cowen 43rd Annual Health Care Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Announces Appointment of David Topper as Chief Financial Officer
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential Preferred Therapy for High Risk Cardiovascular Disease
From NewAmsterdam Pharma Company B.V.
Via GlobeNewswire
Tickers FLAC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.